Detail akcie Nascent Biotech online

Business Summary: Nascent Biotech, Inc. is a phase II clinical-stage biopharmaceutical company, which is engaged in developing monoclonal antibodies for the treatment of various types of cancer. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company's lead candidate, Pritumumab (PTB), is a human monoclonal antibody (Mab) that has progressed to Phase 2 clinical trials for the treatment of Brain Cancer. Pritumumab is a fully natural human IgG antibody that was derived using proprietary technology from a B-cell isolated from a tumor draining lymph node of a patient with cervical cancer. Its other products include CLNH5 and MultiPharm. MultiPharm is a proprietary platform technology that may have additive and synergistic effects not only for cancer therapy but also for diabetes, autoimmunity, and transplantation.
Financial Summary: BRIEF: For the three months ended 30 June 2024, Nascent Biotech Inc revenues was not reported. Net loss applicable to common stockholders decreased 30% to $377K. Lower net loss reflects Interest expense decrease of 99% to $2K (expense), Consulting decrease of 39% to $139K (expense), Clinical trials decrease of 97% to $1K (expense).